The food-grade status and probiotic activity of lactic acid bacteria (LAB) make them attractive hosts for production and oral delivery of therapeutic heterologous vaccines and other proteins, yet these bacteria currently do not achieve recombinant protein expression at levels comparable to those seen in Escherichia coli and Saccharomyces cerevisiae. Limited levels of expressed recombinant protein per cell most likely constrain the vaccine's immunogenic potential with respect to the magnitude and specificity of the immune response. With the goal of increasing recombinant protein expression per cell in Lactococcus lactis IL1403, a model LAB, we have constructed and evaluated a new vector that permits simultaneously-induced expression of GFP, a model recombinant protein, and antisense RNA inhibition of the clpP-encoded intracellular protease. While silencing of the rational target clpP does not lead to increased GFP per cell, the new dual-expression system provides an efficient and potentially high-throughput metabolic engineering tool for strain improvement.